Journey Medical Corp. DERM 深 滬
已收盤 10-17 16:00:00 美东时间
7.20
-0.200
-2.70%
華盛通- 最 高7.45
- 今 開7.32
- 成交量 5.23万股
- 最 低 7.13
- 昨 收 7.40
- 總市值 1.89亿
- 52周最高 8.8999
- 市盈率 靜 --
- 換手率 0.20%
- 52周最低 3.535
- 委 比 -67.37%
- 總股本 2630.98万
- 歷史最高 10.20
- 量 比 0.28
- 振 幅 4.32%
- 歷史最低 1.02
- 每 手 1
- 風險率 1.02%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多上海医药多西环素胶囊获得美国FDA批准文号
近日，上海医药下属常州制药厂有限公司收到美国食品药品监督管理局的通知，其关于多西环素胶囊的简略新药申请已获得批准。基本情况 药物名称 多西环素胶囊 剂...
10-14 18:47
AbbVie's Allergan Pushes Global Skin Quality Drive With Wider SKINVIVE Launch In 2025
Allergan Aesthetics, an AbbVie company (NYSE:ABBV), today announced the roll-out of SKINVIVE by JUVÉDERM® in 35 additional markets this year bringing the total to 57 globally in 2025. This expansion underscores
09-23 17:20
Journey Medical Corporation to Participate in September 2025 Investor Conferences
Journey Medical Corporation’s CEO Claude Maraoui to attend two September 2025 investor conferences in New York City. The events include H.C. Wainwright’s Global Investment Conference on Sept 8 and Lake Street Capital’s BIG9 Conference on Sept 11. Both are in NYC with fireside chat and 1x1 meetings format. The company focuses on marketing FDA-approved dermatological products and currently markets eight branded prescription drugs.
09-03 12:30
Journey Medical Corp Enters New Sales Agreement
The latest announcement is out from Journey Medical Corp ( ($DERM) ). On August...
08-29 05:53
HC Wainwright & Co. Initiates Coverage On Journey Medical with Buy Rating, Announces Price Target of $13
HC Wainwright & Co. analyst Brandon Folkes initiates coverage on Journey Medical (NASDAQ:DERM) with a Buy rating and announces Price Target of $13.
08-25 19:35
SkinMedica® Unveils Its Newest Hydration Hero
By the makers of BOTOX® Cosmetic (onabotulinumtoxinA), SkinMedica® introduces a next generation amino acid–based cleanser: HA5® Hydra Collagen Hydrating Foaming Cleanser. IRVINE, Calif, Aug....
08-19 20:00
Journey Medical Corporation to Present at the Emerging Growth Conference
Journey Medical Corporation (NASDAQ: DERM) announced that its CEO, Claude Maraoui, will present a corporate overview at the Emerging Growth Conference on August 20, 2025, at 12:35 p.m. ET via a virtual video webcast. For more details or to register, visit EmergingGrowth.com. An archived webcast will be available later. Journey Medical specializes in marketing FDA-approved prescription drugs for dermatological conditions and currently offers eight...
08-18 12:30
Earnings Scheduled For August 12, 2025
Companies Reporting Before The Bell • Smithfield Foods (NASDAQ:SFD) is expected...
08-12 16:32
Examining the Future: Journey Medical's Earnings Outlook
Journey Medical (NASDAQ:DERM) will release its quarterly earnings report on Tue...
08-12 03:03
Journey Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11
Journey Medical Corporation will ring the Nasdaq closing bell on August 11, 2025, to celebrate its 4-year anniversary as a publicly traded company and the commercial launch of Emrosi™ for rosacea treatment. Claude Maraoui, CEO, highlighted the company's progress and confidence in Emrosi's success to drive profitability and positive EBITDA this year. A live stream of the event will be available.
08-07 12:30
